If 6 months they can probably pull top line data by next summer, easily. This thing wont be on the market for 3-4 years though.So lets say they start the trial in the next couple months. Patient enrollment might be complete by the end of the year, and we expect the trial to be 6 months. If they take 3 months to analyse the data we could realistically expect the results Q4 2022/Q1 2023.
What do you guys think?